U.S. Pharma Stock News

Kyverna Therapeutics (KYTX) just delivered positive topline data from its registrational KYSA-8 trial in stiff person syndrome and paired that milestone with a planned $100 million follow on equity raise, a combination the market is watching closely. See our latest analysis for Kyverna Therapeutics. The news has turbocharged sentiment, with Kyverna’s latest share price at $10.82 after a 1 day share price return of 23.23 percent and a year to date share price return of 176.02 percent. This...

Fitch’s decision to lift Hillman Solutions (HLMN) to a BB credit rating puts a fresh spotlight on the stock, as lower perceived credit risk can subtly shift how investors think about its long term upside. See our latest analysis for Hillman Solutions. Even with a softer 1 day share price return of around negative 1 percent and a year to date share price return in the low single digit negatives, the 3 year total shareholder return near 30 percent suggests underlying momentum is still intact as...

Jones Lang LaSalle (JLL) just cleared another earnings hurdle, topping third quarter profit expectations even as revenue came in slightly light. The stock has pushed to fresh highs on the back of that consistency. See our latest analysis for Jones Lang LaSalle. That backdrop of steady execution has kept investors leaning in, with the latest 1 month share price return of around 9 percent helping push JLL to roughly 32 percent year to date and supported by an impressive 3 year total shareholder...

If you are wondering whether Southwest Airlines at around $41.72 is still a deal or if the easy money has already been made, you are not alone. This stock is back on a lot of investors' radar. The share price has jumped 9.9% over the last week and 27.1% over the past month, lifting year-to-date gains to 25.0% and putting the 1-year return at 30.5%, despite the stock still being slightly down, about 2.5%, over 5 years. These moves have come as investors reassess airlines that are rebuilding...

Erasca (ERAS) just locked in U.S. patent protection through 2043 for its pan RAS candidate ERAS-0015 and elevated Robert Shoemaker to chief scientific officer, signaling a tighter focus on its RAS pipeline. See our latest analysis for Erasca. The move comes after a powerful run, with a 30 day share price return of 32.95 percent and a 90 day share price return of 105.39 percent. The 1 year total shareholder return of 30.42 percent contrasts with a still negative 3 year total shareholder return...

Levi Strauss (LEVI) kicked off the year with higher net revenues and organic global sales growth for the Levi's brand, a clear sign that its push into beauty, accessories, and home goods is gaining traction. See our latest analysis for Levi Strauss. That backdrop helps explain why the stock’s 25.95% year to date share price return and 32.01% one year total shareholder return look solid, even with a softer 90 day share price patch as investors reassess growth and execution risk. If Levi’s...

World Kinect (WKC) just paired a fresh 150 million dollar share repurchase authorization with a reaffirmed 0.20 dollar quarterly dividend. This combination usually signals management is comfortable with cash generation and balance sheet flexibility. See our latest analysis for World Kinect. Even with the buyback and dividend decision, the stock has been drifting lower, with a roughly negative 10.6 percent year to date share price return and a mid single digit negative one year total...

Earlier this month, Capital One Financial released its monthly report on credit card charge-off and delinquency metrics for the period ended November 30, 2025, giving investors fresh data on its credit quality and lending performance. This routine yet closely watched disclosure offers a timely window into how effectively Capital One is managing consumer credit risk across its loan book. We’ll now examine how these updated charge-off and delinquency figures could influence Capital One’s...

Mizuho recently initiated coverage on Equitable Holdings with an Outperform rating, citing the company’s capital-light model, expanding retirement market presence, and consistent shareholder returns through rising dividends and share repurchases. This fresh analyst endorsement reinforces the view that Equitable’s repositioning toward lower capital intensity and recurring retirement-focused revenues is central to its long-term story. We’ll now explore how Mizuho’s upbeat initiation,...

SCTbio’s new collaboration with Fortrea Holdings (FTRE) is turning heads, as investors weigh how this advanced therapies partnership could reshape development timelines, costs, and Fortrea’s role across the crowded cell and gene therapy pipeline. See our latest analysis for Fortrea Holdings. That backdrop helps explain why the stock’s 1 month share price return of 54.27 percent and 3 month share price return of 55.77 percent look like momentum is rebuilding, even though the year to date share...

Five Below (FIVE) just delivered a better than expected third quarter, lifting sales, profits and investor mood in one go, and management quickly backed that up by raising full year guidance. See our latest analysis for Five Below. That earnings beat and guidance hike come after a powerful run, with the share price up roughly 83% year to date and a 1 year total shareholder return near 73%, signaling strong, building momentum as investors reassess Five Below's growth runway and risk...

In early December 2025, Johnson Controls’ Sensormatic Solutions launched AI-enabled Orbit AI sensors and Video AI cameras that track shopper behavior without using personal identifiable information, feeding insights into ShopperTrak Analytics to help retailers improve layouts, merchandising, and staffing decisions. This push into privacy-conscious, AI-powered in-store analytics highlights Johnson Controls’ effort to deepen its role in data-driven building solutions beyond traditional...

WD-40 Company's ( NASDAQ:WDFC ) dividend will be increasing from last year's payment of the same period to $1.02 on...

We wouldn't blame Palo Alto Networks, Inc. ( NASDAQ:PANW ) shareholders if they were a little worried about the fact...

Unfortunately for some shareholders, the Eshallgo Inc. ( NASDAQ:EHGO ) share price has dived 25% in the last thirty...

Oppenheimer’s downgrade of IAC (IAC) to Perform, and the roughly 3% slide that followed, has shifted the conversation from upside potential to whether the market is fairly pricing its structural constraints. See our latest analysis for IAC. That downgrade lands after a strong 1 month share price return of about 14% and a modest rebound over 3 months. Set against a still negative year to date share price return and a bruising 5 year total shareholder return decline, it suggests recent momentum...

Bit Digital (BTBT) just reshuffled its leadership bench, with one director resigning, the long serving chair shifting to an independent role, and crypto industry veteran Amanda Cassatt joining the board to help steer its next phase. See our latest analysis for Bit Digital. Those boardroom shifts come as the stock has pulled back sharply, with a 30 day share price return of minus 14.11 percent and a one year total shareholder return of minus 51.97 percent. At the same time, the three year...

Wondering if Chubb at around $312 a share is still worth buying, or if the real upside has already been priced in? This breakdown is designed to help you decide with a clear valuation lens. The stock has climbed 5.2% over the last week, 5.8% over the past month, and is up 14.7% year to date, adding to an impressive 54.0% gain over 3 years and 122.5% over 5 years. These moves have come as investors focus more on high quality insurers with strong underwriting discipline and robust balance...

W. P. Carey Inc. recently raised its quarterly cash dividend to US$0.920 per share, or US$3.68 annualized, a 4.5% increase over the 2024 fourth quarter, payable on January 15, 2026 to shareholders of record on December 31, 2025. This higher payout underlines management’s emphasis on steady income for investors, even as a long-serving board member departs for health reasons. We’ll now explore how this dividend increase may influence W. P. Carey’s income-focused investment narrative and...

Barclays just bumped Cboe Global Markets (CBOE) up to Overweight after taking a closer look at its index options engine, the surge in retail options activity, and a tighter focus on core derivatives. See our latest analysis for Cboe Global Markets. That bullish call from Barclays lands after a powerful run, with Cboe’s share price up strongly on a year to date basis and its five year total shareholder return nearing a triple. However, recent pullbacks suggest momentum is cooling rather than...

Why United Bankshares Stock Is Getting Attention Now United Bankshares (UBSI) has quietly outperformed many regional peers, with the stock up about 9% over the past month and roughly 7% year to date. This has drawn fresh attention from income focused bank investors. See our latest analysis for United Bankshares. The recent 1 month share price return of about 9 percent, alongside a solid 3 year total shareholder return in the mid teens, suggests momentum is quietly building as investors warm...

Essex Property Trust has issued US$350 million of 4.875% senior notes due 2036 and its board has declared a regular quarterly dividend of US$2.57 per share, payable on January 15, 2026 to shareholders of record on January 2, 2026. This refinancing, aimed at addressing an upcoming US$450 million maturity while preserving balance sheet flexibility, directly ties Essex’s funding costs to its long-horizon West Coast multifamily investment plans. We’ll now examine how refinancing with 4.875%...

Earlier this month, Castle Biosciences announced that an independent expert consensus panel published a paper endorsing its DecisionDx-Melanoma test as a clinically validated tool that adds prognostic value beyond standard staging in cutaneous melanoma care. The panel’s unanimous agreement, based on 26 studies covering more than 7,500 patients, positions DecisionDx-Melanoma as part of best-practice risk stratification and treatment planning, while separate meta-analysis data support...

In recent days, several Wall Street firms, including JP Morgan, Barclays, and Keybanc, reiterated cautious “Underweight” views on Consolidated Edison while updating their outlooks following the company’s earlier sale of its clean energy business and renewed focus on regulated New York utility operations. Investor attention was further drawn by a rare insider transaction disclosed this month, as Director John Killian sold a small portion of shares after a year otherwise marked by insider...